Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8551898 | 0.83 | MAPT (0.31) | MAPTCCR6CYP1A2 | |
| SCHEMBL3668017 | 0.82 | CCR6 (0.36) | LMNAMAPTSMN1; SMN2CCR6CYP1A2 | |
| SCHEMBL3674251 | 0.79 | TSHR (0.38) | CCR6CYP1A2 | |
| SCHEMBL8548071 | 0.77 | L3MBTL1 (0.34) | MAPTCYP1A2 | |
| SCHEMBL3670052 | 0.74 | RXFP1 (0.40) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL8608349 | 0.74 | KMT2A (0.39) | LMNAMAPTCYP1A2 | |
| SCHEMBL3668151 | 0.73 | GPR35 (0.42) | LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL8113307 | 0.70 | GRIN2D (0.42) | SMN1; SMN2CYP1A2 | |
| SCHEMBL8123057 | 0.69 | ALDH1A1 (0.40) | LMNAMAPTRECQLSMN1; SMN2CYP1A2 | |
| SCHEMBL8128520 | 0.69 | CAPN9 (0.31) | LMNAMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220074-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | claimed |
| EP-2220075-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | claimed |
| WO-2009062318-A1 | 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | claimed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | claimed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | claimed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | claimed |
| WO-1998023599-A1 | UREA AND THIOUREA DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-2010527-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2009-01-07 | — | — | EP | disclosed |
| EP-1883451-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007118314-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-1998027097-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS NEUROPROTECTIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998023599-A1 | UREA AND THIOUREA DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |